KB Essential Healthcare 30 DST


KB Exchange Trust is pleased to offer a diversified four property dialysis portfolio, structured as a Delaware Statutory Trust. This multi-asset portfolio consists of approximately 34,575 square feet located across four states and is leased to two separate tenants on long-term net leases. Both tenants are Fortune 500 companies and carry an investment grade or corporate credit rating. All of the properties have stipulated rental increases over the anticipated holding period. The Trust has obtained a non-recourse loan in the amount of $8,025,000. The loan is structured on a 10-year term at 3.86% rate with five years interest-only and five years of amortization.

Download Investment Summary
Full Name:
E-mail Address:
Phone Number:
Are You In An Exchange?:
Home Kingsbarn Realty Capital
DST Net-Lease Properties
DST Multifamily Net-Lease
Recent Transactions
DST 101
1031 Exchange
Document Vault
ABOUT KB EXCHANGE TRUST

ABOUT FRESENIUS KIDNEY CARE

About DaVita, Inc.

DaVita Inc. (“DaVita”) is a Fortune 500® company. As the second largest provider of kidney care in the United States, DaVita is traded on the New York Stock Exchange (NYSE: DVA). Delivering dialysis services to patients with chronic kidney failure and end-stage renal disease, DaVita is located in nine different countries, 46 states, and the District of Columbia. DaVita also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the US. In 2018, DaVita’s consolidated revenue was approximately $11.4 billion with an operating income of over $1.5 billion. Approximately 90% of DaVita’s 2018 consolidated revenue was derived from their outpatient hemodialysis clinics. The company currently has a Standard & Poor’s rating of “BB” and has experienced tremendous growth over the past decade.
DaVita, Inc. serves approximately 39% of the total dialysis outpatients in the United States.

 

About Fresenius Kidney Care

Fresenius Kidney Care, a division of Fresenius Medical Care (NYSE: FMS) is the nation’s leading provider of kidney care, hospital services and renal products. Fresenius is a $22 billion worldwide company with over 120,734 employees and a network of 3,928 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. Dialysis is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure. Fresenius is a Fortune magazine Global 500 company with a Standard & Poor’s credit rating of 'BBB.'
Around 3.4 Million patients with chronic kidney failure worldwide regularly undergo dialysis treatment. Fresenius Medical Care performed approximately 50 million dialysis treatments in 2018.


FINANCIAL SUMMARY

› Offering Price: $16,025,000

› Loan Amount: $8,025,000

› Equity Offering: $8,000,000

› Minimum Investment: $100,000

› Projected Cash Flow (Year 1)1: 6.00%

INVESTMENT HIGHLIGHTS

› Current Occupancy 100% (as of Jan 7, 2020)

› Monthly Distributions 1

› Cost segregation studies provided for
  accelerated depreciation

› DST Structure Ideal for 1031 Exchanges

› Annual rental increases

› Investments Starting from $100,000

Call Us To Discuss This Investment Opportunity: 800.242.1000


Ron Glasgow
Managing Director,
KB Exchange Trust
rglasgow@kbxtrust.com

This website does not offer to sell, or a solicitation of an offer to buy, securities. Offers can only be made through the Private Placement Memorandum which contains various and important risk disclosures. This web site does not purport to be complete and should be viewed in conjunction with the Private Placement Memorandum. An investment of this sort is speculative and involves a high degree of risk. Projections of future performance contained herein are based on specific assumptions discussed more fully in the Private Placement Memorandum and do not constitute a guaranty of future performance.

DST Interests in any of the properties displayed on this website may be sold only to "accredited investors," as defined in Regulation D under the U.S. Securities Act of 1933, as amended (the "Securities Act"), which, for natural persons, refers to investors who meet certain minimum annual income or net worth thresholds. Offers and sales of DST interests have not and will not be registered under the Securities Act or the laws of any U.S. state or non-U.S. jurisdiction and may be offered only pursuant to an exemption from such registration. Neither the U.S. Securities and Exchange Commission nor any other regulatory authority has passed upon the merits of an investment in the DST Interests, has approved or disapproved of DST Interests or passed upon the accuracy or adequacy of this website and any supplementary materials describing the DST Interests. DST Interests are also not subject to the protections of the Investment Company Act of 1940, including the limitations on self-dealing, affiliated transactions and leverage contained therein. DST Interests are subject to legal restrictions on transfer and resale in accordance with the governing documents of the Trust and applicable securities laws, and investors may be unable to sell or transfer their DST interests. In addition, there is no public market for the DST interests and no such market is expected to develop in the future. Investing in the DST securities involves risk, and investors should be able to bear the loss of their investment.

Securities offered through registered representatives of Colorado Financial Service Corporation, Member FINRA and SIPC. Kingsbarn and Colorado Financial Service Corporation are separate entities. Any information provided on this site has been prepared from sources believed to be reliable, but is not guaranteed by Kingsbarn Real Estate Capital or Colorado Financial Service Corporation and is not a complete summary or statement of all available data necessary for making an investment decision. Any information provided is for informational purposes only and does not constitute a recommendation. Check the background of this investment professional on FINRA’s BrokerCheck